Predicting complications of diseases such as rheumatoid arthritis (RA) as well as the efficacy and toxicity of drugs used to treat the disease based on an understanding of genetic differences is leading to the development of highly individualized, personal medicine.
It is possible that better understanding of the genetic and epigenetic interactions in MM may reveal new understanding of MM pathogenesis, new disease biomarkers and hopefully the development of novel, individualized treatment strategies, contributing to a more effective disease control.
Induced pluripotent stem cells could potentially help to elucidate the complex mechanisms of the disease and lead to the development of more effective individualized treatment.
The WIN Project is unique among the 10 state projects in its focus on individuals with co-occurring physical and behavioral health conditions, including SMI, its implementation through Medicaid Managed Care plans, the development of individualized person-centered goals, and the use of person-directed flexible wellness accounts.
Using TBI biomarkers increases the predictive value of outcome calculators and improves the development of individualized treatment courses, thereby reducing outcome severity [ 70].
Moreover, the recognition of recurrent rearrangements in central signaling pathways provides a basis for the development of selected and individualized targeted therapeutics in ESCC.
Long-term follow-up care should include education, development of individualized follow up plans and screening for health problems in accordance with the Children's Oncology Group survivor guidelines.
Unique features of this intervention include the use of a population-based sample, telephone and internet-based assessments, and development of a highly individualized web-based intervention.
Additionally, mining genomic information will identify unique gene/pathway interactions that could be particularly useful for the development of novel, combination, and individualized therapies.
The ambivalence of these findings has led to development of the hypothesis that the effectiveness of intensive glucose control likely depends on individualizing treatment (e.g. treatment modality and glycaemic target) to account for CV risk and other factors [ 8].
